FIGS Inc-CL A (NYSE:FIGS) delivered a powerful fourth-quarter earnings beat, sending its shares sharply higher as investors cheered a significant acceleration in revenue growth and a dramatic expansion in profitability.
The direct-to-consumer healthcare apparel brand reported results for the fourth quarter and full year of 2025 that far exceeded analyst expectations, showcasing robust demand momentum and improved operational efficiency. The market's immediate positive reaction reflects relief and optimism after a period of investor scrutiny over the company's growth trajectory.
Earnings and Revenue: A Substantial Beat
The core of the earnings surprise lay in both top-line and bottom-line performance. FIGS not only returned to strong double-digit revenue growth but did so at a pace that left Wall Street forecasts far behind.
- Q4 2025 Revenue: $201.9 million, a 33% increase year-over-year.
- Analyst Estimate for Q4 Revenue: Approximately $168.3 million.
- Q4 2025 GAAP EPS: $0.10 per diluted share.
- Analyst Estimate for Q4 EPS: $0.021 per share.
The revenue beat of over $33 million and the earnings per share figure coming in nearly five times higher than estimates underscore a quarter of exceptional execution. This performance marked a significant acceleration from the full-year revenue growth of 13.6%, indicating strong momentum heading into the new fiscal year.
Market Reaction and Performance
The market's verdict was decisively positive. Following the earnings release, FIGS stock experienced a substantial after-hours gain. This surge adds to positive momentum over recent weeks, suggesting the results have catalyzed a reassessment of the company's near-term prospects and profitability potential.
Key Highlights from the 2025 Report
Beyond the headline beats, the earnings release detailed several foundational strengths and strategic successes:
Strong Growth Across Segments and Geographies:
- Scrubwear revenue grew 35.1% year-over-year in Q4, while non-scrubwear grew 26.4%.
- International net revenues surged 55.1%, highlighting the global expansion opportunity.
- Active customers increased 9.4% to 2.9 million, while net revenue per active customer and average order value both rose, indicating healthy customer engagement and monetization.
Significant Profitability Improvement:
- Full-year net income skyrocketed to $34.3 million (5.4% margin) from $2.7 million (0.5% margin) in 2024.
- Adjusted EBITDA for the year increased by $22.7 million to $74.5 million, with the margin expanding to 11.8% from 9.3%.
- The company generated $53.0 million in free cash flow, strengthening its balance sheet.
Management Commentary and Outlook: CEO Trina Spear stated the quarter "capped off a remarkable 2025," driven by execution that "gained steady momentum throughout the year." She emphasized that the "COVID overhang" is past and pointed to structural industry advantages as tailwinds.
CFO Sarah Oughtred highlighted "tremendous demand momentum, improving profitability and record cash on the balance sheet." The company provided formal guidance for 2026, projecting:
- Net revenue growth of 10% to 12% versus 2025.
- An Adjusted EBITDA margin between 12.7% and 12.9%.
This outlook appears roughly in line with current analyst expectations for the full year, suggesting management is confident in sustaining its newfound profitability profile even as growth normalizes from the exceptional Q4 pace. The company also noted it expects Q1 2026 revenue growth in the "low-20% range."
Conclusion
FIGS' fourth-quarter report served as a potent reminder of the brand's resonance within the healthcare community and its operational leverage when execution aligns. The massive beats on both revenue and earnings, coupled with clear progress on profitability and a solid forward outlook, have reignited investor enthusiasm. The challenge now will be to maintain this momentum and demonstrate that the strong Q4 was a inflection point towards durable, profitable growth rather than an isolated peak.
For a detailed look at historical earnings, future estimates, and analyst projections, visit the FIGS earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, nor a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.